Lannett Company (LCI) announced that the U.S. FDA recently approved its Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg, the therapeutic equivalent to the Apotex's Paxil CR Extended-Release Tablets. According to data from IMS Health, total U.S. sales in 2015 of Paroxetine Extended Release-Tablets were ~$122M.